NCT06993974

Nitazoxanide in Patients With Ulcerative Colitis

Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Mesalamine	Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
DRUG	Nitazoxanide	Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.

Timeline

• Start date: 2025-05-30
• Primary completion: 2026-08-20
• Completion: 2026-12-20
• First posted: 2025-05-29
• Last updated: 2025-06-27

Locations

1 site across 1 country: Egypt